Trial Profile
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic retinopathy
- Focus Adverse reactions
- Acronyms RECOVERY
- 01 Mar 2022 Results assessing changes of the retinal vascular bed area (RVBA) in mm2 on stereographically projected ultrawide field fluorescein angiography images in eyes with proliferative diabetic retinopathy after antivascular endothelial growth factor injection, published in the Retina.
- 24 Mar 2021 Status changed from active, no longer recruiting to completed.
- 21 Sep 2017 Status changed from recruiting to active, no longer recruiting.